BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1593 related articles for article (PubMed ID: 25865047)

  • 1. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
    Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
    Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
    Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
    Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
    Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M
    Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
    Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
    Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
    Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H
    Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
    Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
    Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
    Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
    Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.